Recurrent Gastrointestinal Carcinoid Tumor
12
0
0
10
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
16.7%
2 terminated out of 12 trials
83.3%
-3.2% vs benchmark
0%
0 trials in Phase 3/4
30%
3 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (12)
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer